Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	520.76	230.44	4.16
Cash & Short-Term Investments	520.76	230.44	4.16
Cash Growth	12424.24%	5442.09%	-
Receivables	-	0.07	0.07
Prepaid Expenses	0.76	0.57	0.76
Total Current Assets	521.51	231.07	4.98
Property, Plant & Equipment	0.54	0.82	0.64
Other Long-Term Assets	2.12	2.03	0.94
Total Assets	524.17	233.98	6.7
Accounts Payable	1.96	3.19	5.14
Accrued Expenses	12.21	11.61	18.76
Current Portion of Leases	0.31	0.29	-
Total Current Liabilities	14.48	15.09	23.9
Long-Term Leases	0.14	0.37	-
Other Long-Term Liabilities	-	0.02	0.09
Total Liabilities	14.62	15.47	23.98
Common Stock	0.01	0	0
Additional Paid-In Capital	709.61	4.25	2.23
Retained Earnings	-200.06	-153.02	-101.04
Total Common Equity	509.56	-148.77	-98.8
Shareholders' Equity	509.56	218.51	-17.28
Total Liabilities & Equity	524.17	233.98	6.7
Total Debt	0.45	0.66	-
Net Cash (Debt)	520.31	229.78	4.16
Net Cash Growth	12413.54%	5426.29%	-
Net Cash Per Share	158.23	396.10	9.69
Filing Date Shares Outstanding	54.42	34.26	0.43
Total Common Shares Outstanding	54.41	0.64	0.43
Working Capital	507.03	215.99	-18.91
Book Value Per Share	9.37	-232.15	-230.26
Tangible Book Value	509.56	-148.77	-98.8
Tangible Book Value Per Share	9.37	-232.15	-230.26

Source: S&P Capital IQ. Standard template. Financial Sources.